NEW YORK--(BUSINESS WIRE)--Feb. 14, 2006--Axonyx Inc. (NASDAQ:AXYX) today reported a significant reduction in the plasma levels of beta-amyloid 1-42 (A beta-42) in healthy human subjects treated with Phenserine for 35 days. This additional analysis was recently completed as part of the program to identify a partner for the further development of Phenserine.
